Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.39 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116364 | 0.89 | BCHE (0.33) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL26494066 | 0.87 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL2116363 | 0.85 | GNAO1 (0.37) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL1615678 | 0.83 | GNAO1 (0.50) | GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL2118266 | 0.83 | GNAO1 (0.36) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL25075207 | 0.83 | GNAI3 (0.38) | GNAO1GNAI3GNAI1POLBHTT | |
| SCHEMBL19604917 | 0.82 | GNAO1 (0.58) | GNAO1GNAI3GNAI1SIGMAR1KCNH2 | |
| SCHEMBL26850541 | 0.81 | GNAO1 (0.44) | GNAO1GNAI3GNAI1SIGMAR1RAD52 | |
| SCHEMBL2116406 | 0.80 | GNAI3 (0.39) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL20224766 | 0.80 | GBA1 (0.41) | GNAO1GNAI3GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158652-B2 | 1-Difluoromethyl-5-{4-[3-(1-piperidinyl)propoxy]phenyl}-2(1H)-pyridone; compounds act as histamine-H3 receptor antagonistic substances or inverse-agonistic substances; useful as preventives or remedies for various circular system diseases, nervous system diseases, metabolic system diseases | MSD K.K. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20080269287-A1 | Substituted Pyridone Derivative | MSD K.K. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1820797-A1 | SUBSTITUTED PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269287-A1 | Substituted Pyridone Derivative | HRH3, HRH4, HRH1 | GNAO1 2673/4885GNAI3 3293/4885GNAI1 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.